FRI study shows the potential of an inhaled P13K delta inhibitor in COPD-exacerbations.
A well powered study with FRI as primary endpoint shows the potential of an inhaled P13K delta inhibitor in COPD-exacerbations.
A recent paper, published in the Int. Journal of Chronic Obstructive Pulmonary Disease showed that addition of nemiralisib to usual care delivers more effective recovery from an acute exacerbation and improves lung function parameters including siVaw and FEV1.
This study adds to the growing body of evidence highlighting the value of imaging to better understand and treat lung diseases.
The study can be read here: https://pubmed.ncbi.nlm.nih.gov/34113093/
Categorised in: Articles / July 9, 2021 3:20 pm /Tags: COPD, FRI, P13K